NASDAQ:APLT

Applied Therapeutics Stock Forecast, Price & News

$19.73

-0.49 (-2.42 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$19.32

Now: $19.73▼

$20.32

50-Day Range

$19.91

MA: $22.25▼

$24.15

52-Week Range

$13.58

Now: $19.73▼

$57.39

Volume147,188 shs

Average Volume83,628 shs

Market Capitalization$443.69 million

P/E RatioN/A

Dividend YieldN/A

Beta1.27

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company's preclinical stage products include AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Overall MarketRank^™

1.43 out of 5 stars

Medical Sector

511th out of 1,923 stocks

Pharmaceutical Preparations Industry

253rd out of 773 stocks

3.5 Analyst's Opinion

Consensus Rating
Applied Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $63.50, Applied Therapeutics has a forecasted upside of 221.8% from its current price of $19.73.
Amount of Analyst Coverage
Applied Therapeutics has received no research coverage in the past 90 days.

2.2 Community Rank

Outperform Votes
Applied Therapeutics has received 52 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Applied Therapeutics has received 67 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Applied Therapeutics has received 56.30% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Applied Therapeutics and other stocks. Vote “Outperform” if you believe APLT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APLT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Applied Therapeutics does not currently pay a dividend.
Dividend Growth
Applied Therapeutics does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $677,364.00 in company stock.
Percentage Held by Insiders
Only 31.50% of the stock of Applied Therapeutics is held by insiders.
Percentage Held by Institutions
54.25% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Applied Therapeutics are expected to grow in the coming year, from ($4.51) to ($4.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Applied Therapeutics is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Applied Therapeutics is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:APLT

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.appliedtherapeutics.com

Phone212-220-9226

Employees22

Debt

Debt-to-Equity RatioN/A

Current Ratio5.99

Quick Ratio5.99

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)($3.55)

Net Income$-45,510,000.00

Net MarginsN/A

Return on Equity-85.39%

Return on Assets-70.42%

Miscellaneous

Outstanding Shares22,488,000

Market Cap$443.69 million

Next Earnings Date3/12/2021 (Estimated)

OptionableNot Optionable

$19.73

-0.49 (-2.42 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive APLT News and Ratings via Email

Sign-up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.

Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions

How has Applied Therapeutics' stock price been impacted by Coronavirus?

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, APLT shares have decreased by 33.3% and is now trading at $19.73.
View which stocks have been most impacted by COVID-19.

Is Applied Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Applied Therapeutics stock.
View analyst ratings for Applied Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Applied Therapeutics?

Wall Street analysts have given Applied Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Applied Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Applied Therapeutics' CEO?

1,448 employees have rated Applied Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Applied Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Applied Therapeutics' next earnings date?

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Applied Therapeutics.

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics, Inc. (NASDAQ:APLT) posted its quarterly earnings data on Tuesday, November, 17th. The company reported ($1.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.02) by $0.31.
View Applied Therapeutics' earnings history.

What price target have analysts set for APLT?

5 equities research analysts have issued 12 month price targets for Applied Therapeutics' stock. Their forecasts range from $44.00 to $85.00. On average, they anticipate Applied Therapeutics' share price to reach $63.50 in the next twelve months. This suggests a possible upside of 221.8% from the stock's current price.
View analysts' price targets for Applied Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Applied Therapeutics' key competitors?

Some companies that are related to Applied Therapeutics include Zentalis Pharmaceuticals (ZNTL), uniQure (QURE), Rhythm Pharmaceuticals (RYTM), Olema Pharmaceuticals (OLMA), Generation Bio (GBIO), COMPASS Pathways (CMPS), Arcturus Therapeutics (ARCT), Ironwood Pharmaceuticals (IRWD), Constellation Pharmaceuticals (CNST), Nkarta (NKTX), Heron Therapeutics (HRTX), Endo International (ENDP), Supernus Pharmaceuticals (SUPN), Ocular Therapeutix (OCUL) and Amneal Pharmaceuticals (AMRX).
View all of APLT's competitors.

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), The Walt Disney (DIS) and Raytheon Technologies (RTX).

Who are Applied Therapeutics' key executives?

Applied Therapeutics' management team includes the following people:

Dr. Shoshana Shendelman Ph.D., Chairman, Founder, Pres, CEO & Sec. (Age 42, Pay $550k)
Dr. Riccardo Perfetti, Chief Medical Officer (Age 62, Pay $757.09k)
Mr. Charles Silberstein, CFO & Head of Bus. Devel.
Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 52)
Mr. Adam Hansard, Chief Commercial Officer

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.

What is Applied Therapeutics' stock symbol?

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

How do I buy shares of Applied Therapeutics?

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Applied Therapeutics' stock price today?

One share of APLT stock can currently be purchased for approximately $19.73.

How big of a company is Applied Therapeutics?

Applied Therapeutics has a market capitalization of $443.69 million. The company earns $-45,510,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis. Applied Therapeutics employs 22 workers across the globe.

What is Applied Therapeutics' official website?

The official website for Applied Therapeutics is www.appliedtherapeutics.com.

How can I contact Applied Therapeutics?

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here